The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | The current landscape of hemophilia treatment: an update from ASH 2023
Glaivy Batsuli, MD, Stanford University, Stanford, CA, shares her excitement about the variety of treatment options that are now available for hemophilia, given the recent approval of gene therapy. She mentions that this could add a layer of complexity when deciding which treatment avenue to go down and emphasizes the importance of involving patients in the decision-making process. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
